Vall d'Hebron Institute of Oncology (VHIO)
Elena Serrano Carballal began their work experience in 1995 as a predoctoral fellow at CBMSO. Elena then became a postdoctoral fellow at the Universitat de Barcelona / Spanish National Cancer Research Centre (CNIO) in 2004. In the same year, they joined IIB Sant Pau - Fundació Institut de Recerca Hospital de Sant Pau - Centre CERCA as a bioinformatics specialist. Over the years, Elena held various roles at IIB Sant Pau, including Coordinator of Scientific and Technical Services Platforms and Responsible for the Genomics and Transcriptomics Platform. From 2012 to 2023, they served as the Scientific Director of Biobanco IIB Sant Pau. Currently, Elena is the Head of the High Technology Unit at Vall d'Hebron Institute of Oncology (VHIO), beginning in 2023.
Elena Serrano Carballal has a postgraduate degree in Genómica, Proteómica y Bioinformática from the Universitat de Barcelona, which they completed in 2004. Prior to that, they obtained a doctoral degree in Ciencias Biológicas with a specialization in Biología Molecular from the Universidad Autónoma de Madrid, which they achieved between 1997 and 2003.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.